Millington, NJ, United States of America

Dorothea Kominos

USPTO Granted Patents = 6 

 

 

Average Co-Inventor Count = 10.7

ph-index = 3

Forward Citations = 139(Granted Patents)


Company Filing History:


Years Active: 2005-2019

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Dorothea Kominos

Introduction

Dorothea Kominos is a notable inventor based in Millington, NJ (US). She has made significant contributions to the field of biotechnology, particularly in the development of antibodies that target specific peptides. With a total of 6 patents to her name, her work has implications for pharmaceutical compositions and therapeutic applications.

Latest Patents

One of her latest patents involves nucleic acids encoding antibodies to Kallidin and des-Arg-Kallidin. This invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. Additionally, it includes pharmaceutical compositions, nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors, and host cells for producing such antibodies or their fragments. The methods outlined in this patent also describe how to use these antibodies to modulate Kallidin or des-Arg10-Kallidin activity or to detect these peptides in vitro or in vivo.

Career Highlights

Throughout her career, Dorothea has worked with prominent companies in the pharmaceutical industry, including Sanofi and Aventis Pharmaceuticals Inc. Her experience in these organizations has allowed her to develop her innovative ideas into practical applications.

Collaborations

Dorothea has collaborated with several professionals in her field, including Alla Pritsker and Nicolas Baurin. These collaborations have likely contributed to her success and the advancement of her research.

Conclusion

Dorothea Kominos is a pioneering inventor whose work in biotechnology has led to significant advancements in the development of therapeutic antibodies. Her contributions continue to impact the pharmaceutical industry and enhance our understanding of peptide interactions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…